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ABSTRACT
Precision medicine incorporates patient-level covariates to tailor treatment decisions, seeking to
improve outcomes. In longitudinal studies with time-varying covariates and sequential treatment
decisions, precision medicine can be formalized with dynamic treatment regimes (DTRs): sequences
of covariate-dependent treatment rules. To date, the precision medicine literature has not addressed
a ubiquitous concern in health research - measurement error - where observed data deviate from the
truth. We discuss the consequences of ignoring measurement error in the context of DTRs, focusing
on challenges unique to precision medicine. We show - through simulation and theoretical results -
that relatively simple measurement error correction techniques can lead to substantial improvements
over uncorrected analyses, and apply these findings to the Sequenced Treatment Alternatives to
Relieve Depression (STAR*D) study.
1 Introduction
Precision medicine is a framework in which medical treatment decisions are based on patient-level data. At its core,
precision medicine aims to ‘treat patients, not diseases’, reflecting the principle that the best treatment decision is
informed by all relevant, available data on the patient, not solely their diagnosis. This can manifest in the simple
case of a single treatment decision (the one-stage setting), but can be readily generalized to longitudinal treatment
regimes where all available patient-level data (both present and past) can inform treatment decisions. One way of
codifying such a process in the precision medicine framework is through the use of Dynamic Treatment Regimes
(DTRs): sequences of decision rules tailored to patient-level covariates. Precision medicine in general, and DTRs in
particular, have received a great deal of research attention in recent years.[1, 2, 3, 4]
A key focus of the DTR framework is estimating the optimal sequence of treatment decisions that maximize an
expected outcome, conditional on available patient-level data at each decision point. This may be a simple rule based
on a single covariate (such as “prescribe treatment if the patient consumes fewer than 1300 calories a day”), or may
be a highly complex set of treatment decisions which depend on many factors. Finding optimal treatment rules can be
especially challenging in the observational data setting, wherein observed treatments may themselves be informed by
patient-level information. Estimation of such rules has received considerable attention in the biostatistical literature,
with the development of numerous estimation procedures.[4, 5]
Measurement error refers to any process through which observable data do not equal the true underlying values of
interest.[6] Common examples include blood pressure (typically elevated in clinical settings) [7] or self-reported
caloric intake.[8] While measurement error may arise through a variety of mathematical mechanisms, the underlying
concern is that analyses which do not account for such error may produce unpredictable and unreliable conclusions.
These so-called naive analyses, along with many relevant correction methods, have been widely studied in both linear
[9] and non-linear [10] models.
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Despite the abundance of literature surrounding both DTRs and measurement error, there has yet to be a substantial
attempt to assess the estimation of the former in the presence of the latter. Precision medicine encompasses both esti-
mation and inference (in studying treatment effects) but also prediction (in applying decision rules to future patients).
While estimation and inference have received considerable attention in the measurement error literature (outside of
the context of precision medicine), prediction has not. Some argue for the use of error-prone variables to predict an
outcome of interest directly. This argument advocates exploiting the dependence between our error-prone variable and
the outcome, ignoring the underlying causal relationship between the true variable and the outcome. Then, if there
is a sufficiently strong relationship between the outcome and observed measure, prediction may remain valid. This
argument is correct for some models,[6] however, it is not always clear when it is valid. It has been shown that even in
a standard regression setting, it may be necessary to correct for error to ensure valid prediction.[11]
Whether the goal is to assess the efficacy of a treatment regime, or to aid in future treatment decisions, the literature in
standard modeling contexts gives us reason to believe that many of the same concerns will exist in precision medicine,
and DTRs specifically. We will investigate these issues, establish when and how precision medicine analyses may be
affected, and investigate - through simulation and theoretical results - straightforward measurement error correction
techniques within the DTR framework. We further apply our methods to analyze the Sequenced Treatment Alternatives
to Relieve Depression (STAR*D) study.[12, 13]
2 Methodology
A wide variety of methods are available both for DTR estimation and measurement error correction. Common tech-
niques for the former include Q-learning [14, 15] and inverse probability weighting,[16] along with the more complex
and robust G-estimation [17, 18] and augmented inverse probability weighting techniques.[19] Dynamic weighted
ordinary least squares (dWOLS) offers a compromise between these broad classes of approach, offering robustness to
model misspecification while maintaining straightforward implementation.[20] Classification-type approaches, such
as outcome weighted learning, have also recently grown in popularity.[21, 22]
The measurement error literature boasts a similar range of options with a familiar trade-off between simplicity of theory
and theoretical properties. For example, regression calibration [23, 24] and simulation extrapolation (SIMEX) [25, 26]
are both general methods, which make few assumptions regarding the underlying data. This results in comparatively
simple estimators which are consistent in linear models, but which can make no general consistency guarantees in non-
linear models.[10] In contrast, methods such as the conditional score[27, 28], under correct distributional assumptions,
and the corrected score[29, 30] offer consistent estimators for a larger class of models, at the cost of more complex
implementation.
As the first substantive work on the interface between DTRs and measurement error, we will limit our focus to
methodologies that afford straightforward implementation. DTR estimation will be carried out via dWOLS,[20]
whose regression-based implementation is complemented by the measurement error correction method of regression
calibration.[23, 24]
To establish notation, and the modeling framework upon which our methodology relies, in this section we will in-
troduce the specifics of a one-stage, error-free DTR, and discuss the estimation procedure using dWOLS. We will
then extend to the multistage case. Finally, we will discuss regression calibration generally, clarifying the specific
corrections that we will use.
2.1 DTRs and dWOLS
In a one-stage DTR we make a single binary treatment decision (A) per patient. We take A = a ∈ {0, 1} to denote
some binary treatment option, such as standard treatment (a = 0) compared to an intervention (a = 1). We are
concerned with an outcome variable Y , chosen such that larger values are preferred. Patient information available
immediately prior to the decision being made is denoted X. The optimal DTR will then take X = x as input for a
patient and return A = aopt, such that Y is maximized in expectation. Formally, aopt = arg maxaE[Y |A = a,X =
x;β, ψ], where the mean is modeled as
E[Y |A = a,X = x;β, ψ] = f(xβ ;β) + γ(xψ, a;ψ) (1)
with xβ and xψ representing two (possibly identical) subsets of the covariates x, and β and ψ are model parameters.
We often take x = (1,x) to allow for a baseline effect (or intercept) to be captured in f .
This mean decomposition includes a component f(xβ ;β) which does not depend on the treatment, and a component
γ(xψ, a;ψ) which captures the effect of treatment. These are the so-called treatment-free and blip components, re-
spectively. The combination of the treatment-free and blip models (as outlined in Equation (1)) is referred to as the
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outcome model. The treatment decision impacts the outcome only through the blip. As such, estimation of the optimal
DTR is equivalent to finding the decision rule which maximizes γ(xψ, a;ψ). We therefore only need to estimate the
ψ terms correctly to determine the optimal DTR.
Often, we take γ(xψ, a;ψ) = aψ′xψ to be a linear function of the covariates multiplied by the treatment indicator,
meaning aopt = 1 if ψ′xψ > 0 and aopt = 0 otherwise. If we correctly specify the full outcome model then standard
regression procedures may be applied. However, as our treatment decision does not depend on the treatment-free
component directly, we may wish to seek methodology that does not depend on its correct specification in full. For
example, even with the treatment-free model misspecified, we could nevertheless proceed with correct specification of
the blip if a and x were independent, but this is seldom a reasonable assumption in our observational setting (where
treatment decisions may be made based on patient-level data).
dWOLS, along with some other methods such as the aforementioned G-estimation [18] and augmented inverse prob-
ability of treatment weighting,[19] account for this by requiring the specification of a treatment model, modeling the
probability of receiving the intervention given the individual’s covariates. In dWOLS, this allows the calculation of
patient-level weights, which we denote v(a,x) for a patient with covariates x receiving treatment a. These weights
are designed to ‘balance’ the covariates. Any weights which satisfy
pi(x)v(1,x) = (1− pi(x))v(0,x), (2)
where pi(x) = P (A = 1|X = x), will suffice for balance. The use of v(a,x) = |a− pi(x)| is recommended.[20]
In the one-stage setting, dWOLS is simply a weighted ordinary least squares regression with weights satisfying Equa-
tion (2) and an outcome model structure as indicated by Equation (1). The resulting estimators for ψ are then doubly
robust: as long as the blip model is correctly specified, and at least one of the treatment or treatment-free models is
correctly specified, the estimators for ψ will be consistent.
These methods easily extend to multistage processes. A K-stage DTR will have K total treatment decisions made,
which we index by j. We wish to estimate the optimal decision for stage j, given all information available immediately
prior to the decision. We now subscript the covariate vector and the treatment decision, xj and aj , to denote the
measurements taken and the observed decision at stage j, respectively. We use over- and under-line notation to refer
to the past and future respectively, so that (for example) xj = (x1, . . . ,xj) and aj+1 = (aj+1, . . . , aK). Finally, for
notational convenience, we define a variable to represent the patient’s history prior to the stage j treatment decision:
hj = (xj ,aj−1). We now expand Equation (1), given the above notation, to
E[Y |H = h;β, ψ] =
K∑
j=1
{
fj(h
β
j ;βj) + γj(h
ψ
j , aj ;ψj)
}
(3)
where hβj and h
ψ
j , are (possibly identical) subsets of the history vector hj . We take fj to be the treatment-free model
for stage j, specifying the impact of hβj on the outcome. This impact is not mediated by treatment. Conversely, γj is
the blip model for stage j, which indicates the impact of hψj on the outcome. This effect is mediated by treatment (aj).
The stage j blip function in this multistage setting is defined as the marginal impact of a patient receiving treatment aj ,
compared to a patient who received standard treatment at stage j (aj = 0), with an identical history and who goes on
to receive optimal, though not necessarily identical, treatment in the future. That is, γj(hj , aj ;ψj) = E[Y aj ,a
opt
j+1 −
Y aj−1,0,a
opt
j+1 |Hj = hj ], where Y a† refers to the counterfactual outcome Y , which is potentially unobserved, under a
treatment regime specified by a†.
There is an alternative formulation for the outcome model, which provides a more intuitive characterization for inter-
preting dWOLS. The mean outcome can be defined such that
E[Y |H = h] = E[Y opt|H = h]−
K∑
j=1
µj(hj , aj ;ψj), (4)
where Y opt gives the theoretically optimal outcome (under the optimal DTR) and the µj constitute penalty terms for
non-optimal treatment. Here µj are referred to as regrets, and are the contrast in outcomes between a patient who
receives optimal treatment at stage j, and the same patient receiving treatment aj at stage j, assuming the patient is
treated optimally thereafter. Formed this way, the observed outcome is equal to the optimal outcome less all negative
effects deriving from suboptimal treatment. The regrets may be expressed in terms of the blips, namely µj(hj , aj) =
γj(hj , a
opt
j )− γj(hj , aj).
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There is a recursive nature to the multistage DTR analysis as the treatment decision at stage j impacts all future
decisions. In dWOLS we begin by analyzing the final stage of treatment, then work backwards, at each stage generating
a pseudo-outcome which removes the effects of future treatment from the outcome. Letting y˜K = Y , we define the
j-th pseudo-outcome as y˜j = y˜j+1 +
(
γj(hj , a
opt
j )− γj(hj , aj)
)
= y˜j+1 + µj(hj). That is, we ‘add back’ the stage
j regret, effectively removing it from the outcome. This allows the pseudo-outcome at stage j to be interpreted as the
outcome for a patient who receives their particular regime up to stage j, and then is optimally treated afterwards. We
could continue to use the blip formulation of the outcome model. In this case we once again take y˜′K = Y , and then
define y˜′j = y˜
′
j+1 − γj(hj , aj). In practice, the regret setup is more commonly implemented, and we will continue to
use it (unless otherwise stated).
Estimation using dWOLS in the multistage setting then follows a three step procedure. First, define weights for each
stage vj , which satisfy Equation (2), using xj as the covariate. Second, starting at stage K, and working iteratively
backwards, solve the weighted regression of y˜j on the patient history hj . Third, define y˜j−1, and repeat. If the blip
and at least one of the treatment or treatment-free models are correctly specified at each stage j, this process will lead
to consistent estimators for all ψj .
In order to estimate a DTR we further require two assumptions on our data, whether they are randomized or obser-
vational. First, we make the stable unit treatment value assumption (SUTVA).[31] SUTVA requires that a patient’s
outcome is not influenced by another patient’s treatment assignment. This is typically reasonable, though may be
violated, for instance, when the intervention is a vaccine and the effects of herd immunity influence all observed out-
comes. Second, we make the no unmeasured confounders, or sequential ignorability, assumption.[32] No unmeasured
confounders requires that all common causes of treatment (at each stage j) and future potential covariates or outcomes
must be measured in the history. That is, conditional on the available history, treatment must be independent of future
potential covariates and outcome. While this assumption will typically hold in randomized studies, it is untestable in
the observational framework, and so must be carefully validated based on the applicable subject matter. We will make
these assumptions for the remainder of our discussion.
2.2 Measurement Error and Regression Calibration
In order to correct for measurement error we need to make assumptions regarding the structure of the error. If we
take X to be the true covariate and X∗ to be an error-prone observation of X , then we assume some form for
X∗ = g(X,U). Here U is the random noise which induces the error. While any specific application may suggest
a particular form for the error model (g), two commonly used models are the classical additive, and the multiplicative
error models. In the classical additive model we take g(X,U) = X + U , and assume that E[U ] = 0, and that U has
constant covariance, not depending on X , given by cov(U) = ΣU . Moreover, we assume that U is independent of (or
sometimes uncorrelated with) both X , and any other covariates we observe (without error) Z. In the multiplicative
model we take g(X,U) = XU , and assume that E[U ] = 1, and again, cov(U) = ΣU . We make the same indepen-
dence assumptions. Note, that while the notation above tends to imply that X (and as such U ) is a scalar, the same
models can be extended to vector-valued covariates; we make no distinction, and have selected notation for simplicity
of exposition. Both the additive and multiplicative models provide unbiased measurements of X , in the sense that
E[X∗|X,Z] = X . When we have an outcome of interest, Y , we also tend to classify error as either differential or
non-differential. Non-differential error refers to the case where, given {X,Z}, our outcome Y is conditionally inde-
pendent of X∗. Errors may be differential if, for instance, measurements are taken subsequent to the outcome being
observed (such as a cancer diagnosis affecting how a patient responds to questions about their historical smoking
habits). This is seldom the case in our framework.
Error correction techniques (such as our choice of regression calibration) typically require additional data beyond
what is used in standard inferential procedures to learn about the size (and structure) of the error. These may come
in the form of validation, replicate, or instrumental data. Validation data consist of a subsample of the observations
where both the true and error-prone observations are available. Replicate data consist of repeated measurements of
the error-prone covariates for some subset of the individuals. Instrumental data, also known as instrumental variables
(IV), refer to additional covariates that are related to the true values, but which are (typically) uncorrelated with both
the error observed in the covariate, and the variability in the model after accounting for the true covariates.[10] An IV,
T is called unbiased for X , if E[T |X,Z] = X . Replicate measurements can be viewed as a specific type of unbiased
instrumental variables. While validation data are typically considered ideal, they are often unavailable in practice.
Instead, we focus on the use of unbiased IVs, referred to as error-prone proxies, including replicate measurements.
The premise of regression calibration is to replace the unobserved X in our models with an estimated X̂ =
E[X|Z,X∗]. We then proceed with standard analysis on the predicted values, adjusting the standard errors as needed.
Consider a single patient, with k unbiased proxies of the true covariate, denoted X∗1 , . . . , X
∗
k . A common procedure
4
Spicker and Wallace Measurement error and precision medicine. A PREPRINT
for determining X̂ = E[X|Z,X∗] is taking the so-called best linear unbiased prediction (BLUP) approach, which in-
volves approximating the conditional mean as a linear equation.[23, 24] We use a plug-in estimator for the theoretical
BLUP, given by
X̂ = µX + [ΣXX∗ ΣXZ ]
[
ΣX∗X∗ ΣX∗Z
ΣZX∗ ΣZZ
]−1 [
X∗ − µX
Z − µZ
]
. (5)
Regression calibration was originally proposed for a fairly general class of additive error models, with independent
and identically distributed replicate measurements. [23] When we have identically distributed replicate measures, it is
sensible to take the mean ofX∗1 , . . . , X
∗
k for use asX
∗ in this equation. When the error models differ between proxies,
it seems unlikely that the most effective way to combine the proxies is a simple mean. Intuitively, the observations
which are less disturbed by error ought to contribute more toX∗. Our estimators are a generalization of those typically
used when replicates are available, [10] where we take X∗ =
∑k
j=1 δjX
∗
j , for a set of weights δj , choosen either for
the interpretation of the estimator or to reduce variability. The specific details of the implementation of our estimators
are contained in Appendix A.
Applying this correction, when errors are additive, results in consistent estimators in linear models. In non-linear
models, some authors have described the estimators as “nearly consistent”.[33] By this they mean that, while we cannot
guarantee consistency of all parameters in the models, we can often make claims about reduced bias or consistency of
some parameters. For instance, in log-linear models, regression calibration estimators will consistently estimate the
slope parameters while inconsistently estimating the intercept.[10] Of greatest concern for our work, outside of linear
models, is the utility of regression calibration for logistic regression models. Here, the phrasing “nearly consistent” is
taken to mean that the correction, in many situations, provides a great reduction in the bias of the parameter estimates.
Further, when the main concern with the fitted logistic regression is the probability estimates, regression calibration
provides a reasonable approximation to the truth, when neither the slope parameters, nor the conditional variance of
X given {X∗, Z} are too large. Specifically,
P (A = 1|Z,X∗) ≈ H
[
α0 + α
′
XX̂ + α
′
ZZ
(1 + α′XΣX|Z,X∗αX/1.72)1/2
]
,
where H(x) = (1 + exp(−x))−1 is the inverse-logit (expit) function, α are the parameters of the logistic regression,
and ΣX|Z,X∗ gives the conditional covariance of X given {Z,X∗}.[10] In general, the denominator will attenuate
the estimates for the model parameters. When the denominator of this approximation is close to 1, however, this
attenuation will be small, and the estimator using regression calibration takes an approximately correct form.
While the corrections we consider are motivated by non-differential classical additive error models, a wider class of
error models can be accommodated by the methods we introduce. Any non-differential error model, with (1) more than
one unbiased proxy available for X , (2) uncorrelated errors between proxies (that is, the covariance between any two
unbiased measurements equals the covariance ofX , ΣX ), and (3) the covariance of all of the unbiased proxies given as
ΣX +M for suitable constant M , can be interchanged if necessary. This would include the multiplicative error model
introduced above. However, when errors are multiplicative, it is generally advisable that transformations are applied
to the measured values, to use a scale on which the errors are additive. [?] While the existing asymptotic theory, and
most implementations of regression calibration correction, rely on the additive structure, the modified estimators we
present are computable under this wider class of models. In our simulation studies (Section 4) we demonstrate that the
corrections perform adequately under slight deviations from additivity. Still, if there is good reason to believe that all
proxies are subject to non-additive error, which is transformable to an additive model, we would advise that analysts
make these transformations, as asymptotic justifications for the presented methods on those models are lacking.
3 Measurement Error in Dynamic Treatment Regimes
With little work to date concerning measurement error in DTRs and precision medicine, we shall limit attention to the
case of errors in patient-level covariates, assuming treatments and outcomes are measured correctly. In this section we
will illustrate that, in addition to concerns arising from measurement error that are common to traditional modeling
settings, there are considerations which are unique to the structure of DTRs. We discuss these considerations alongside
various theoretical observations.
First, we motivate the construction of valid estimators in the one-stage setting, providing a theoretical guarantee of
sample covariate balance in the presence of measurement error. Next, we illustrate how these estimators can be
extended to the multistage setting, paying specific attention to the estimation of pseudo-outcomes. We then discuss
how confidence intervals may be constructed using a modified bootstrap procedure. Finally, we focus on the process of
determining optimal treatments in the future, reframing the estimation as a prediction problem, and discuss the merits
of error correction in this context.
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X
X∗
Y
A
Figure 1: A directed acyclic graph representing the assumed impact of measurement error in the DTR setting. Here X
refers to error-free (unobservable) covariates, X∗ refers to some combination of the error-prone proxies, A is a binary
treatment indicator, and Y is a numeric outcome of interest.
3.1 Blip Parameter Estimation
To estimate a DTR with dWOLS, we must specify the outcome and treatment models. We assume that a biological
process (or similar) relates the true covariate values X to the outcome Y , whereas treatment decisions can only be
made based on the error-prone observed values X∗. This structure is shown graphically in Figure 1. The treatment
decision may be based on a single observed proxy, for instance X∗1 , or on some combination of these proxies, for
instance X∗ = 1k
∑k
i=1X
∗
i .
Recall that dWOLS produces doubly robust estimators through the principle of covariate balance. If our treatment-free
model is misspecified, then correct specification of the treatment model will induce covariate balance in X , (that is
E[X|A = 1] = E[X|A = 0] in the weighted data set), leading to consistent estimation of the blip parameters.[20]
In the error-prone setting, if we employ regression calibration using X̂ in our outcome models, we wish to induce
covariate balance not between X and A, but between X̂ and A. Following the proof by Wallace and Moodie which
justifies the choice of weights,[20] we might intuitively speculate that any weights which satisfy pi(X̂)v(1, X̂) =
(1 − pi(X̂))v(0, X̂) will induce covariate balance in X̂ . In the error-free setting weights of the form v(a, x) =
|a− E[A|X = x]| are recommended, suggesting the use of weights of the form v(a, x∗) = |a− E[A|X̂ = x∗]| may
prove suitable. We observe the following Result.
Result 1. Let X∗ = (X∗1 , . . . , X∗k) be observed as a set of unbiased proxies for X , and denote the regression cal-
ibration estimates of X , based on X∗, by X̂ . Take P (A = 1|L) = H(α′L), where L is any tailoring covariate
(vector), which may (but does not necessarily) contain X . Using the weights v(A, X̂) = |A − Pˆ (A = 1|X̂)|, where
Pˆ (A = 1|X̂) is estimated through a simple logistic regression, the weighted sample means, conditional on A, will be
equivalent. Given the above setup,∑n
i=1 v(1, x
∗
ri)Aix
∗
ri∑n
i=1 v(1, x
∗
ri)Ai
=
∑n
i=1 v(0, x
∗
ri)(1−Ai)x∗ri∑n
i=1 v(0, x
∗
ri)(1−Ai)
.
Proof of Result 1: See appendix.
Result 1 states that the estimation procedure alone ensures that, within the sample, the weighted means are equivalent
between observations with A = 1 and with A = 0, regardless of the true underlying treatment model. The idea of
using sample balance as a small-sample proxy for true balance has been explored in a traditional balancing score
setting.[34] We will show through simulations that, in many situations, this sample balance suffices to maintain the
double robustness of dWOLS.
When introducing regression calibration we discussed that, in general, the parameters are not consistently estimated
in a logistic regression. This discussion is less directly relevant to our present scenario. The reason is that, under our
assumed model, the “true” covariates used to inform treatment are the observed covariates, which by assumption are
X∗. While X∗ is error-prone with respect to the underlying value of interest, X , and as such the outcome model,
it is not error-prone with respect to the treatment model, where decisions are informed using X∗. As a result, when
applying regression calibration to the treatment model, we are using X̂ in place of X∗, not in place of X . This
remains an approximation – one which is shown in simulations to adequately induce balance – but not the standard
approximation discussed in the literature.
6
Spicker and Wallace Measurement error and precision medicine. A PREPRINT
3.2 Multistage DTRs with Error
Having established an approach for blip parameter estimation in the single-stage problem, we now consider the mul-
tistage case, which further requires the estimation of the pseudo-outcomes, y˜i. If using the regret formulation, then to
estimate the pseudo-outcome we must estimate aˆoptj , as well as the blip function itself. Consider, for notational ease, a
two-stage DTR, which has a linear specification for γ2(x2, a2) = a2(ψ20 +ψ′21x2). Then a
opt
2 = I(ψ20 +ψ
′
21x2 > 0).
In the error-free case, we have aˆoptj = I(ψ̂20 + ψ̂
′
21x2 > 0) rendering ̂˜y1 = Y − µ1 − µ2 + (aˆopt2 − a2)(ψ̂20 + ψ̂′21x2).
Under the condition that ψ̂20 = ψ20 and ψ̂21 = ψ21, then aˆ
opt
2 = a
opt
2 and µ̂2 = (aˆ
opt
2 − a2)(ψ̂20 + ψ̂′21x2), simplifying
the estimated pseudo-outcome to ̂˜y1 = Y − µ1, which is the same as the theoretical quantity y˜1.
This simplification will not (necessarily) occur in the error-prone case for two reasons. First, even if the ψ̂ are correctly
estimated, the use of X̂2 in place of X2 will result in a residual term between the blip functions. Second, the estimated
optimal treatment aˆopt2 may differ from the true optimal treatment. Assuming that we have ψ̂20 = ψ20 and ψ̂21 = ψ21,
then we have
µˆ2 − µ2 =
(
Aˆopt2 −Aopt2
)(
ψ20 + ψ21X̂2
)
+
(
Aopt2 −A2
)
ψ′21
(
X2 − X̂2
)
. (6)
If instead of the regret formulation, we compute the pseudo-outcome as described in the blip formulation (and as such
do not need to estimate the optimal treatment), we will be left with the residual term γ2 − γ̂2 = A2ψ′21
(
X2 − X̂2
)
.
While it is not possible, without access to X2 directly, to guarantee that these two sources of error are completely
eliminated, we are afforded some flexibility in how they are computed. In particular, if we estimate the blip parameters
using the regression calibration correction, and assume that they have been correctly estimated, we could separately
choose a covariate, X∗2 , to use for estimating y˜.
In the blip characterization X∗2 should be chosen in such a way as to minimize X2 −X∗2 . Noting that X̂2 is chosen to
be the (linear) estimator of X2 which minimizes the mean squared error (MSE), this gives reasonable justification for
selecting X̂2. It is also worth noting that if A2 = 0 the blip pseudo-outcome is exactly correct. As such, practitioners
applying this method with this characterization may wish to consider a regression calibration conditional on A2 = 1
(that is, estimate the BLUP only for those who received second stage treatment), which would minimize the MSE
among linear estimators for only those patients who contribute to the biased pseudo-outcomes.
The regret characterization warrants slightly more involved consideration. The second term in Equation (6) has an
impact dictated by X2 − X∗2 , as in the blip formulation. The first term, however, relies on a difference of indicator
functions. If γ2 >> 0 or γ2 << 0, such that there is an unambiguous optimal treatment for the individual, then
controlling |γ̂2 − γ2| leads to Âopt2 = Aopt2 . In this situation, γ̂2 near γ2 simplifies to the condition that X∗2 is near
X2, and so we can once again rely on the justification that X̂2 minimizes the MSE to motivate the selection of the
regression calibration correction. If we have that |γ2| ≤  for a sufficiently small , such that the optimal treatment
is ambiguous, then it no longer suffices to have γ̂2 near γ2 (as even small perturbations between these quantities may
lead to Âopt2 6= Aopt2 ). However, if we do have γ̂2 near γ2, then we can also make the claim that |γ̂2| is small, relatively
speaking. The magnitude of the first term in Equation (6) is given by |γ̂2|, therefore, selecting an estimator to be
near γ2 will ensure that either (1) Â
opt
2 is likely to be optimal in the event that there is a large treatment effect, or (2)
that the magnitude of the error produced will be small when Âopt2 is not optimal. This provides a heuristic rationale
to use the regression calibration correction in order to estimate the pseudo-outcomes. In order to improve the MSE
by conditioning, as was possible in the blip characterization, we would want to limit focus to patients for whom
Aopt2 6= A2. However, Aopt2 is not observable, and as such this is not a possible strategy.
There are obvious limitations to this justification. The first is that, in certain settings, it may be possible to derive an
estimator which minimizes a loss function on the classification of optimal treatments. Further, restricting consideration
to linear estimators of X2 may be ill-advised. Finally, a metric other than MSE may be preferable to measure the
distances in this setting. The first issue is a problem that is linked to optimal treatment recommendation (which we
investigate briefly in Section 3.4). The second concern extends beyond the estimation of pseudo-outcomes, and in such
situations where linear estimators perform poorly, alternative corrections should be considered. There are extensions
to regression calibration which provide higher order corrections which may be suitable.[10] Finally, where MSE is
an inappropriate metric, practitioners of the methodology may be able to solve for an estimator which optimizes the
desired metric instead. MSE is a generally applicable metric, which ought to serve well in a wide variety of scenarios.
In order to perform dWOLS in an error-prone setting, we ultimately recommend computing the regression calibration
estimates for all error-prone covariates, and then using these values in the treatment, treatment-free, and blip models,
in addition to the estimation of the pseudo-outcomes. This procedure promises consistent parameter estimates under
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correct model specification, sample covariate balance using the weights, and a heuristic justification for acceptability
of pseudo-outcomes. We caution any practitioner applying these methods to be mindful to their particular scenario,
ensuring that the structures we have assumed are reasonable, and that our discussions remain valid for their use case.
3.3 Confidence Intervals and Standard Errors
Regression calibration does not, in general, lend itself to the computation of closed-form variance estimators for
the parameters of interest. There do exist derivations for asymptotic standard errors in generalized linear models,
however bootstrapped confidence intervals tend to be the preferred solution.[10] In the case of dWOLS, there has
been little theoretical development on closed-form variance estimators. They have been derived for the single-stage
setting, where the authors caution that “such variance estimates require careful calculation and coding, and so will
likely not be practical for the typical analyst.” indicating that bootstrap procedures seem to perform satisfactorily in
their exploratory analyses.[20] A modified bootstrap procedure, the m-out-of-n bootstrap, was proposed for use in
Q-learning to handle non-regularity concerns in the estimation of DTRs.[35] The proposed adaptive procedure for
selecting m in Q-learning has been applied, with some success, to dWOLS.[36] It seems that, where measurement
error is a concern, a bootstrap procedure would presently be most suited for estimating confidence intervals for DTR
parameters.
We consider the m-out-of-n procedure, with an adaptive choice of m to construct our intervals. We outline the
fundamentals of the algorithm here, and advise the interested reader to consider the existing literature for a deeper
exploration.[35, 36] The method performs a standard non-parametric bootstrap, where samples of size m < n are
drawn (with replacement), in place of the more conventional n. The theory dictates only that m = o(n), and so in the
finite sample case, we require a procedure for estimating m from the data. We take
m = n
1+ζ(1−p)
1+ζ ,
where both p and ζ are hyperparameters, selected from the data. The parameter p is a measure of the non-regularity for
the model in question, taking values in [0, 1]. Of note, when p = 0, (where we have no regularity concerns), m = n
and this method is equivalent to the standard bootstrap. For a fixed value of n, m ∈ [n1/(1+ζ), n], and so ζ can be
viewed as a parameter which controls the smallest acceptable re-sample size.
We use an adaptive approach which estimates both p and ζ from our data. Consider, for notational simplicity, a two-
stage setting. Non-regularity concerns stem from patients for whom small perturbations in covariates lead to different
optimal treatment decisions. As such, we take pˆ = P̂ (γ̂2 = 0), which we estimate by considering the proportion of
individuals who do not admit a unique optimal treatment decision at the second stage. That is, we construct confidence
sets for the second stage blip, and count the proportion of individuals for whom this set contains 0. To select ζˆ, we use
a double-bootstrap procedure.
We start by setting ζ to be a small value, and then drawB1 samples of size n from the initial data. Within each of these
samples, we estimate pˆ(b1) and the parameters of interest, ψ̂(b1). We then conduct an m-out-of-n bootstrap procedure
with B2 iterations, using the current value of ζ and pˆ(b1) to compute m̂(b1). We use these B2 resamples to form a
confidence interval around the parameters of interest. This is repeated for each of the B1 samples. We then check
the nominal coverage probability, counting the proportion of the B1 intervals which contain the initial estimate, and
if this is at the desired level, we select the present value of ζ for ζˆ. Otherwise, we increment ζ and run the procedure
again. The search space for ζ can be selected as necessary for the application, for instance, restricting the maximum
considered value based on the smallest allowable re-sample size. Once ζˆ and pˆ are selected the bootstrap is performed
with the estimated m̂.
3.4 Future Treatments
While we have focused on the identification of the optimal DTR, an important extension is to consider the implications
that measurement error has on future treatment decisions. One consideration is to frame future treatment decisions
as a prediction (or classification) problem. In such a framing, our goal is not to correctly estimate the causal param-
eters, but rather to correctly classify patients into their optimal treatment categories. As previously discussed, it is
sometimes argued that measurement error corrections are unnecessary in a prediction setting, though this is not uni-
versally applicable.[11] The complexity of DTRs suggest that it is worth considering the utility of error correction for
predictions, and studying the effects of error being ignored.
In order to implement error correction for the assignment of future treatments we must consider what information
is available when making those decisions. If we have measurements available for the entire population we wish to
treat prior to making any treatment decision, we can apply regression calibration directly, and treat based on the
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imputed values. This setting is distinct from the situation where we are making treatment decisions one at a time, and
consequently cannot pool the patients’ information in order to apply regression calibration directly. In this setting we
instead propose a pseudo-correction, where the parameters required to adjust the covariates are made available, from
the fitting stage, for use in the prediction stage. It is also conceivable, for instance due to cost constraints, that during
the study we have error-prone covariates, while future decisions may be informed by the true covariates. Here, the
prediction problem becomes one of predicting across domains.
4 Simulation Studies
We now demonstrate, via simulation, the potential impact of measurement error in the context of DTRs. We emphasize
the issues that are present when conducting a naive analysis, and show the feasibility of regression calibration to largely
correct for the errors in the analysis, as per our preceding discussions.
4.1 Parameter Estimation
We begin by demonstrating the bias present in blip parameter estimates resulting from a naive analysis, and the
robustness of our proposed estimation procedures. First, we consider a simple one-stage setup, with X ∼ N(0, 1),
and assume that we observe two proxy measurements, given byX∗1 ∼ X+N(0, 0.25), andX∗2 ∼ X+ t8. We assume
that the treatment model is given by P (A = 1|X∗1 = w) = H(1 − 0.5w + 1.5 exp(w − 1)), and the outcome model
is specified as Y = X + exp(X) + A(1 + X) +  where  ∼ N(0, 1), independent of all other variables. We are
interested in estimating blip parameters ψ0 = 1 and ψ1 = 1.
In this setting, we consider four analyses, repeated with and without regression calibration, altering which components
of our models are correctly specified. We fit models with (1) neither the treatment nor treatment-free models correctly
specified, (2) only the treatment model correctly specified (where the treatment-free is taken to be linear), (3) only the
treatment-free model correctly specified (where the treatment model is taken to be linear in the logistic scale), and (4)
where both are correctly specified. In all scenarios we simulated 10000 datasets of size n = 1000. The results are
summarized in Figure 2.
When at least one model is correctly specified (analyses (2)-(4)), the naive estimators of ψ0 perform well. In all four
scenarios the naive results are biased for ψ1. Regression calibration results in a clear improvement over the naive
estimators in the results for ψ1 across analyses (2)-(4), where the bias is largely removed. There is a clear, though
dramatically reduced, bias in analysis (2), where the estimates rely on the correct specification of the treatment model
alone.
We further consider extending these analyses to a variety of two-stage DTR settings, adapted from the original dWOLS
paper.[20] In addition, we consider a scenario in which various error model combinations were used. We compare the
estimation of the relevant parameters using the proposed correction to the parameter estimates obtained under an
analysis using a weighted average of the available proxies. For all situations we consider basing treatment on only the
first naive proxy, or on the mean of the available proxies. These results are summarized in the appendix, in Tables 3-7.
In general, we see that whether actual treatment decisions are based on a single error-prone covariate, or on the mean
of multiple proxies, the correction methods are generally applicable. Across the majority of scenarios, the proposed
corrections tend to greatly improve estimates compared to the naive analysis, and yield results which appear broadly
consistent. The corrections work well across a variety of error mechanisms, where performance is only materially
impacted when using a multiplicative gamma distribution to induce the error. These results confirm our comments
regarding the importance of additive error models: the methods are somewhat resilient to these assumptions, but
analysts should be careful when there is good reason to suspect a multiplicative model. When the treatment model is
badly misspecified, we see notable degradation in the quality of the correction. These simulations suggest that careful
consideration must be given to fitting the treatment model.
4.2 Coverage Probabilities
Next, we consider three scenarios to test the applicability of the proposed bootstrap procedure. Due to the compu-
tational demands of the adaptive procedure, it is not feasible to conduct a full simulation study, adaptively select-
ing ζ for each experiment. Instead, we perform the double-bootstrap procedure once under each of the scenarios,
and then consider the m-out-of-n bootstrap for values of ζ surrounding the selected one. In all three scenarios we
take X1, X2 ∼ N(0, 1), and observe two error prone proxies. Scenario 1 takes X∗11, X∗12 ∼ X1 + N(0, 1), and
X∗21, X
∗
22 ∼ X2 +N(0, 1). Scenario 2 takes X∗11 ∼ X1 +N(0, 1), X∗12 ∼ X1 + Unif(−1, 1), X∗21 ∼ X2 +N(0, 1),
and X∗22 ∼ X2 · Gamma(1, 1). Finally, scenario 3 takes X∗11 ∼ X1 + Unif(−1, 1), X∗12 ∼ X1 · Gamma(1, 1),
9
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Figure 2: Blip parameter estimates (true values ψ0 = ψ1 = 1 indicated by dashed lines) for 10000 simulated datasets
(with n = 1000), comparing a regression calibration corrected analysis to a naive analysis, when neither (Analysis 1),
one of (Analyses 2 and 3), or both (Analysis 4) of the treatment and treatment-free models are correctly specified.
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X∗21 ∼ X2+N(0, 0.25), andX∗22 ∼ X2+Unif(−1, 1). For all three scenarios, we take P (Aj = 1|X∗j1 = w) = H(w).
The outcome for scenarios 1 and 2 is given by Y = X1 +X2 +A1(1 +X1) +A2(1 +X2) +  where  ∼ N(0, 1) in-
dependent of everything else. For scenario 3, we introduce an additional binary covariate, Z2, with P (Z2 = 1) = 0.5.
We then take Y = X1 +X2 +A1(1 +X1) +A2(1 +X2 −Z2 −Z2X2) +  where, again,  ∼ N(0, 1). Note that, if
Z2 = 1 then γ2 = 0, meaning that the optimal treatment is not well-defined.
In the first two scenarios we estimate ζˆ = 0.05, while in the third scenario ζˆ = 0.075. For all scenarios we consider
forming bootstrap confidence intervals using (1) a traditional n-out-of-n bootstrap, (2) an m-out-of-n bootstrap where
ζ = 0.05 is used in the adaptive procedure, and (3) an m-out-of-n bootstrap where ζ = 0.10 is used in the adaptive
procedure. For the third scenario, we also include an m-out-of-n bootstrap where ζ = 0.075 is used. The coverage
probabilities are contained in Table 1. We see that the standard bootstrap procedure attained the nominal coverage in all
settings. Taking the selected ζ̂ met the nominal coverage levels in the second scenario, and was slightly conservative
for the first and third scenarios, where taking ζ = 0.10, we obtained mostly conservative intervals. In the third
scenario, all procedures tended to produce conservative results.
4.3 Future Treatment Predictions
To investigate future treatment assignment, we consider a two-stage DTR where X1 ∼ N(0, 1) and X2 ∼ N(A1, 1)
are the true covariates, with replicate observations X∗11 ∼ X1 + t10, X∗12 ∼ X1 + N(0, 1) and X∗21, X∗22 ∼ X2 +
N(0, 0.25). The outcome is given by Y = X1− (Aopt1 −A1)(1−X1)− (Aopt2 −A2)(3− 2X2) + , with  ∼ N(0, 2)
independent of all other parameters. The treatment models take the form P (Ai = 1|X∗i1 = w) = H(1− w).
We partition these analyses into three settings based on the information available at the time treatment decisions (or
predictions) are made. Namely, where we have access to (1) error-prone measurements for only one patient at a
time, (2) error-prone measurements for all patients at once, and (3) the true covariate values for prediction. For these
scenarios we consider the performance of the naive model compared to the corrected model. For the first setting, direct
regression calibration is not possible. Instead, we conduct the pseudo-correction described in Section 3.4, to produce
a corrected estimate. We provide the results for this correction applied when we measure both proxies and when we
only measure a single proxy. In the second setting, we do not fit the naive model (as it is equivalent to scenario (1)).
Each analysis above is run with n = 1000 individuals during the fitting stage, and the treatment assignment is run for
5000 individuals. We repeat the set of simulations 10000 times.
The complete results are provided in Figure 3, where, on average, the corrected methods perform better than the naive
methods in terms of accuracy. The results suggest that, in the worst case scenario, framed as a problem of prediction,
the naive and corrected methods perform comparably. However, there are dramatic gains in terms of optimality of
treatment in the event that additional information is available when assigning future treatments. At stage one, the
pseudo-correction performs favorably using only the second proxy, as compared to only the first proxy, as a result of
its lower variance and higher weight while fitting the estimator. This suggests that if the pseudo-correction is to be
used, and only one proxy will be made available, the proxy with the lowest variance is preferred.
5 STAR*D study
We now illustrate the proposed correction methods through application to data from the Sequenced Treatment Alter-
natives to Relieve Depression (STAR*D) study. The STAR*D study was a multistage randomized controlled trial,
comparing different treatment regimes for patients with major depressive disorder.[12, 13] The study was split into
four phases (with phase two further subdivided into two sub-phases) where, at each phase, different treatment options
were available to patients based on preference and progression through the study. The severity of depression was mea-
sured through the Quick Inventory of Depressive Symptomatology (QIDS) score, where assessment was conducted
during each phase both by the patient (denoted QIDS-S) and by a clinician (denoted QIDS-C). At the end of each
study phase, patients who had a clinician assessed QIDS score less than or equal to 5 were considered to have entered
remission, and were subsequently removed from the study. At phase 1, all patients were prescribed citalopram. At
the end of phase 1, those who did not enter remission entered the second stage where seven treatment options were
available: this phase was characterized by ‘switching’ from citalopram to one of four other treatments options, or
‘augmenting’ treatment by receiving citalopram alongside one of three new treatments. Those who had still not en-
tered remission entered a third (and possibly fourth) phase, where treatment was again switched our augmented with
a variety of possible options. Full details of the study, and of the treatment options, are described elsewhere.[13]
The first and fourth phases of the trial are typically ignored in DTR analysis of these data. We focus on phases two
(merging both sub-phases) and three, which we refer to as stage one and stage two, respectively. Previous analyses
[37] specified QIDS-C as an outcome, and dichotomized treatments differentiating those which contain a selective
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Figure 3: Proportion of optimally treated individuals for 10000 simulated datasets (n = 1000), comparing the pre-
dictive power of naive versus corrected analysis when we (1) make future treatment decisions one-at-a-time, (2) have
recorded information in order to pool patient information, or (3) have the true measurements available to inform
the treatment decision. When single treatment decisions are made, we use a pseudo-correction based on all error-
prone proxies (corrected*) or on a single error-prone proxy (corrected**), using the same parameter estimates for the
pseudo-correction in all three cases. Ranges of optimally treated individuals are shown at stage one and stage two,
separately.
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serotonin reuptake inhibitor (SSRI) and those which do not. These analyses model QIDS-C as a continuous covariate
and consider three tailoring variables: QIDS-C measured at the start of each level (given byQj for stage j), the change
in QIDS-C divided by the elapsed time over the previous level (referred to as QIDS slope, denoted Sj for stage j),
and patient preference (denoted Pj for stage j), a binary indicator specifying whether the patient desired to switch
treatment regimes (Pj = 1) or augment (Pj = 0). Treatment is coded as Aj = 1 if the stage j treatment includes
an SSRI, and a 0 otherwise. Our analysis considers 283 patients, who had all stage one and two covariates measured.
The outcome was taken to be Y = − 12 (QIDS-C1 + QIDS-C2), where QIDS-Cj is the clinician rated QIDS score at
the end of stage j.
Existing analyses of these data make the implicit assumption that clinician scores are error-free measurements. How-
ever, the inclusion of self-assessed measures (QIDS-S), offers a feasible mechanism for exploring measurement error
in this study. If we postulate that there exists a true underlying symptom score for every patient, then we might pro-
pose that both the self-assessed and the clinician scores are surrogate measures for this truth, permitting regression
calibration. We note that our analysis continues to use QIDS-C as the outcome variable, to remain comparable with
previous literature.
5.1 Model Fitting and Comparison
We consider fitting the model using only the clinician ratings, only the self-reports, or using the correction where they
are considered to be error-prone proxies. Following previous analyses of the data, we pose a first stage treatment
model using only first stage preference (P1) and a second stage treatment model using only second stage preference
(P2). For the first stage, the treatment-free and blip models are linear in preference (P1), slope (S1), and initial QIDS
score (Q1). At the second stage, the treatment-free model is linear in preference (P2), slope (S2), starting value (Q2),
as well as stage one treatment (A1). The blip model used only slope (S2) and starting value (Q2). For each of the
settings we conducted an m-out-of-n bootstrap, choosing m using the outlined adaptive procedure. Table 2 contains
the results for parameters estimates and 95% confidence intervals.
Previous analyses have found that the only significant treatment effect was the interaction between stage one treatment
and preference (A1P1), [35] a result that is replicated on our subset of the data when using only clinician scores. If
instead we assume that the self-reported scores represent the true values, we find a significant treatment effect at stage
two, with the interaction between treatment and slope (A2S2). However, if we perform our correction, neither of these
effects remains significant, and we lack evidence for any significant treatment effects. This may be due to increased
uncertainty from the error, but it nevertheless suggests further consideration is required.
6 Discussion
Dynamic treatment regimes provide a powerful framework for characterizing treatment pathways. The theory sur-
rounding optimal DTR estimation is well-developed, with numerous methods available. Measurement error is a
pervasive issue in many scenarios and has consequently received extensive attention. However, there has been no
substantive work which investigates DTRs in an error-prone setting. The errors arising due to measurement error
in the DTR framework are somewhat unique, as the treatment-free, treatment, and blip models are all affected by
measurement error separately. The treatment model no longer depends on the true covariate values, as these are unob-
served, adding extra complexity to the modeling procedure. Additionally, fitting a DTR often requires patient weights
designed to induce covariate balance between a patient’s treatment and their covariates. This balance may not be
guaranteed in the presence of measurement error.
Despite these additional considerations, since DTRs can be effectively estimated through regression methods, and
since measurement error has been well-studied in regression frameworks, extant error correction methods offer a
feasible solution. We investigated the use of regression calibration to correct for covariate measurement error, in the
tailoring covariates, in DTRs with a continuous outcome. We have demonstrated that the application of regression
calibration within the dWOLS analysis framework is an effective technique for substantially reducing the bias present
in an analysis that does not attempt to account for measurement error. Further, the estimates tended to exhibit desirable
behavior across a wide variety of settings, largely preserving the doubly robust property of dWOLS.
The multistage setting poses additional considerations due to the need to estimate the sequence of pseudo-outcomes.
Even when the blip parameters are correctly estimated there is residual bias when constructing the pseudo-outcome
from any error-prone proxy. We argue that using the regression calibration correction to form the pseudo-outcomes can
be justified, using MSE as a metric across the class of linear estimators for the true covariates. While this argument is
largely heuristic, the simulations which were conducted tend to confirm that this procedure often suffices to correct the
parameter estimates. There is opportunity for further theoretical development of these concepts, such as considering
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what metrics are best-suited for the assessment of pseduo-outcome estimates, both when covariates are subject to error
and when they are not.
The m-out-of-n bootstrap with an adaptive choice for m, as proposed to handle non-regularity in the case of error-free
DTRs, seems promising as a mechanism for producing nominal, or at worst conservative, confidence intervals while
using the proposed correction. This is in line with the related theory in both the measurement error and DTR literature,
where the m-out-of-n bootstrap has shown to be effective for dWOLS, and bootstrap methods are broadly useful with
regression calibration. While there is substantial room for the development of rigorous confidence intervals using
dWOLS, both in the error-prone and error-free settings, the recommended m-out-of-n procedure seems to be well-
suited for the task.
While it may seem plausible to view the process of estimating a DTR to form a treatment rule for future patients as a
question of prediction, removing the need for error correction methods, we have demonstrated that the naive estimates
are more highly variable and tend to provide lower rates of optimal treatment as compared to a corrected analysis. Fur-
ther, when there is the possibility of observing error-free patient information when making future treatment decisions,
the gain from using regression calibration in the study is substantial, in terms of the proportion of optimally treated
individuals.
Finally, we demonstrated our methods through analysis of the STAR*D study data, where additional error-prone
proxies were available due to the self-reported QIDS scores, which have typically been ignored in prior analyses
of this dataset. Accounting for errors alters the estimated optimal treatment rules, which may be attributable to the
increased uncertainty that measurement error induces, though it suggests that the true optimal decision rules likely
require further investigation to be correctly identified.
The resolution of measurement error for DTRs is a complex challenge. The approaches proposed in this work rely
on a number of assumptions that may not hold in practice, such as the availability of unbiased instrumental data
or the applicability of the error models explored. Nevertheless, we have demonstrated both the potential impact of
measurement error on so-called naive analyses, and the ease with which considerable gains can be made through
the application of comparatively straightforward analytical techniques. More complex methods (both from the DTR
and measurement error literatures) may elicit further improvements, and we anticipate pursuing these in future work.
Beyond this, errors in the treatment and outcome variables must also be considered, both of which may be investigated
as natural extensions to the results presented here.
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Table 1: Results for the coverage probabilities derived from bootstrap procedures across three scenarios. Intervals
formed using an n-out-of-n (nn) or an m-out-of-n bootstrap, based on the adaptive procedure with ζ (mnζ). Each set
was constructed using 2000 bootstrap replicates, and the experiment was repeated 500 times. Bolded values indicate
those which deviate significantly from the nominal coverage of 0.95. Intervals are shown for treatment at both stages
(Aj), as well as treatment interactions with the error-prone covariates (Xj) and the error-free covariate Z2. Only
scenario 3 used the error-free covariate.
Scenario One Scenario Two Scenario 3
nn mn.05 mn.10 nn mn.05 mn.10 nn mn.075 mn.05 mn.10
A1 0.937 0.958 0.970 0.950 0.962 0.972 0.97 0.98 0.98 0.98
A1X1 0.964 0.970 0.979 0.950 0.958 0.962 0.98 0.99 0.99 0.99
A2 0.961 0.970 0.979 0.950 0.964 0.980 0.97 0.99 0.99 1.00
A2X2 0.940 0.961 0.973 0.952 0.956 0.960 0.96 0.99 0.98 0.99
A2Z2 – – – – – – 0.97 0.98 0.98 0.98
A2X2Z2 – – – – – – 0.97 0.99 0.98 0.99
Table 2: Results for the two-stage blip coefficient estimates comparing an analysis employing the regression calibration
correction to naive analysis using only the clinician or self-reported data. Confidence intervals are computed based on
2000 m-out-of-n bootstrap replicates, where m was chosen based on the described adaptive procedure. Bolded values
indicate treatment effects which are significant at a 95% level. Aj refers to the treatment indicator (1 for those with
an SSRI, 0 otherwise), Pj refers to patient preference to switch (1 with a preference to switch, 0 with a preference to
augment), Qj refers to the starting QIDS score at stage j, and Sj the slope of the QIDS score over the j-th phase.
Error Corrected Clinician Score Self-Reported
Parameter Estimate 95% CI Estimate 95% CI Estimate 95% CI
Stage One
A1 -0.75 (-10.035, 7.934) -0.48 (-6.279, 5.486) 1.35 (-3.784, 6.052)
A1P1 2.72 (-0.186, 5.819) 2.99 (0.898, 5.426) 2.76 (-0.199, 5.826)
A1Q1 0.06 (-0.569, 0.701) 0.07 (-0.346, 0.456) -0.09 (-0.409, 0.253)
A1S1 -1.54 (-6.895, 2.246) -1.04 (-3.768, 1.075) -0.55 (-2.312, 0.887)
Stage Two
A2 -0.31 (-7.045, 6.954) 1.19 (-2.88, 5.521) -0.04 (-4.262, 4.078)
A2Q2 0.09 (-0.479, 0.632) -0.02 (-0.371, 0.3) 0.08 (-0.219, 0.383)
A2S2 1.82 (-2.789, 4.833) 0.94 (-0.82, 2.696) 2.74 (0.297, 5.137)
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A Regression Calibration: Details
We first consider defining the optimal weights δj . In our investigation, we have paid most attention to three separate
sets of weights: (1) using δj = 1k for all k proxy measurements, (2) viewingX
∗ as an estimator forX , and minimizing
the variance of that estimator, which gives δj = Tr (Mj)
−1
[∑k
l=1 Tr (Ml)
−1
]−1
, or (3) treating δj as parameters
in the BLUP and solving, which gives the form δj = Tr (β′βMj)
−1 [∑k
l=1 Tr (β
′βMl)
−1]−1, which we can solve
numerically. Here Mj refers to the j-th matrix in the covariance term. Solving for the BLUP gives us Equation (5).
To implement each of these, we advocate for simple plug-in estimators for each of the corresponding quantities, most
of which can be readily derived through ANOVA-style calculations. Unless otherwise stated, we use
X∗·j ≡
1
n
n∑
i=1
X∗ij
X
∗(j)
i ≡
1
k − 1
k∑
l=1
l 6=j
X∗il
Σ̂X∗j =
1
n− 1
n∑
i=1
(
X∗ij −X∗·j
) (
X∗ij −X∗·j
)
M̂ =
k − 1
kn
n∑
i=1
k∑
j=1
(
X∗ij −X∗(j)i
)(
X∗ij −X∗(j)i
)′
Σ̂
(1)
XX =
1
k

k∑
j=1
Σ̂X∗j − M̂

M̂j = Σ̂X∗j − Σ̂
(1)
XX
µ̂X = µ̂X∗ =
1
n
n∑
i=1
X∗i =
1
n
n∑
i=1
k∑
j=1
δjX
∗
ij
µ̂Z =
1
n
n∑
i=1
Zi
Σ̂ZZ =
1
n− 1
n∑
i=1
(
Zi − Z
) (
Zi − Z
)′
Σ̂XZ = Σ̂X∗Z =
1
n− 1
n∑
i=1
(
X∗i −X∗
)
(Zi − Z)′
Σ̂X∗ =
1
n− 1
n∑
i=1
(
X∗i −X∗
) (
X∗i −X∗
)′
Σ̂
(2)
XX = Σ̂X∗ −
k∑
j=1
δ2j M̂j .
B Proofs of Result 1
Proof of Result 1. Consider an arbitrary logistic regression, explaining A with respect so some covariate T . We will
assume, WLOG, that T is univariate to suppress vector notation, though the same argument holds for vector-valued
covariates. Assume that the model is fit with a sample of (A1, t1), . . . , (An, tn). Computing a maximum likelihood
estimate for P (A = 1|T ) results in solving
∂`
∂α0
=
n∑
i=1
Ai − (1−Ai) exp(α0 + α1ti)
1 + exp(α0 + α1ti)
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and
∂`
∂α1
=
n∑
i=1
ti
Ai − (1−Ai) exp(α0 + α1ti)
1 + exp(α0 + α1ti)
equal to 0. Solving these simultaneously results in
n∑
i=1
Ai
1 + exp(α0 + α1ti)
=
n∑
i=1
(1−Ai) exp(α0 + α1ti)
1 + exp(α0 + α1ti)
and
n∑
i=1
tiAi
1 + exp(α0 + α1ti)
=
n∑
i=1
ti(1−Ai) exp(α0 + α1ti)
1 + exp(α0 + α1ti)
.
The above expressions simplify to:
n∑
i=1
Ai(1− P̂ (A = 1|T = ti)) =
n∑
i=1
(1−Ai)P̂ (A = 1|T = ti)
n∑
i=1
tiAi(1− P̂ (A = 1|T = ti)) =
n∑
i=1
ti(1−Ai)P̂ (A = 1|T = ti)
This of course still holds for T = X̂ , since the exact form of T did not factor into the expression. Then, if the weights
are defined to be |A− P̂ (A = 1|X̂)|, we can see that the ratio of the above two expressions gives us the required form
for sample covariate balance.
C Multistage Simulation Results
To investigate the procedure in the multistage scenario, we consider a variety of related settings formed by varying
different aspects of the model. We take X1 ∼ N(0, 1), with X∗11 ∼ g1(X1) and X∗12 ∼ g2(X1), for error models
g1, g2. We assume that P (A1 = 1|X∗1 = x∗1) = h1(x∗1;α10, α11), with a treatment model h1 and parameters α10, α11.
We also takeX2 ∼ N(A1, 1), withX∗21 = g1(X2) andX∗22 = g2(X2), and P (A2 = 1|X∗2 = x∗2) = h2(x∗2;α20, α21).
The outcome is given by Y = f(X1) + (A
opt
1 −A1) (1 + ψ11X1) + (Aopt2 −A2) (1 + ψ21X2) + , with  ∼ N(0, 1),
where f(X1) is the treatment-free model. We consider five scenarios by altering the above parameters.
1. Considers 10 combinations of (α10, α20), values taken from {−2,−1, 0, 1, 2}, holding the treatment-free
model as linear, both treatment models as linear, the error models as classical additive with N(0, 0.25) distri-
bution, ψ11 = ψ21 = 1.
2. Considers 10 combinations of (ψ11, ψ21), values taken from {−1,−0.1, 0, 0.1, 1}, holding α10 = α20 = 0,
the treatment-free model as linear, both treatment models as linear, the error models as classical additive with
N(0, 0.25) distribution.
3. Considers 5 scenarios for various forms of the treatment-free model, taking f(X1) = X1 (linear), f(X1) =
X1 + X
2
1 (quadratic), f(X1) = X1 + X
2
2 − X31 (cubic), f(X1) = exp(X1) − X31 (exponential), or
exp(X1)I(X1 >= −0.5) (complex). We hold both treatment models to be linear, α10 = α20 = 0,
ψ11 = ψ21 = 1, and the error the error models as classical additive with N(0, 0.25) distribution.
4. Considers 10 scenarios where the treatment models are taken to be one of hj(x∗j ) = αj0 + αj1x
∗
j (linear),
hj(x
∗
j ) = αj0 + αj1x
∗
j + (x
∗
j )
2 (quadratic), hj(x∗j ) = αj0 + αj1x
∗
j + exp(x
∗
j ) (exponential), and hj(x
∗
j ) =
αj0 + αj1x
∗
j + (x
∗
j )
2 + exp(x∗j ) (mixed). We hold the treatment-free model to be linear, α10 = α20 = 0,
ψ11 = ψ21 = 1, and the error the error models as classical additive with N(0, 0.25) distribution.
5. Considers 10 scenarios for various error models, taking gj(Xl) = Xl + N(0, 0.25) (normal), gj(Xl) =
Xl + t10 (approximately normal), gj(Xl) = Xl · Gamma(1, 1) (gamma), or gj(Xl) = Xl · Unif(0.5, 1.5)
(uniform). We hold the treatment-free model to be linear, both treatment models to be linear, α10 = α20 = 0,
and ψ11 = ψ21 = 1.
All analyses are conducted where (X∗1 , X
∗
2 ) is taken to be (X
∗
11, X
∗
21), (X
∗
1 , X
∗
2 ), (X
∗
11, X
∗
2 ), (X
∗
1 , X
∗
21) (that is treat-
ment either depends on the first naive proxy, or on the mean of the two proxies). We take n = 10000 and repeat each
scenario 1000 times. The results for a corrected analysis and a naive analysis are included in Tables 3-7.
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Table 3: Median parameter estimates investigating the impact of treatment probabilities in a multistage DTR, by
varying (α10, α20) as indicated. Blip parameter estimates are compared for n = 10000 individuals, using the corrected
method compared to a naive analysis. The top set of rows of the table use the first error-prone proxy at both stages,
the second set of rows use the mean of proxies at both stages, the third set of rows use the mean at the first stage and
the first error-prone proxy at the second, and the final set of rows use the first error-prone proxy at the first stage and
the mean at the second. Bold values indicate parameters for which the 95% percentile-based interval across the 1000
simulation replicates did not cover the true parameter value.
Regression Calibration Naive
(α10, α20) A1 A1X1 A2 A2X2 A1 A1X1 A2 A2X2
(-2, -2) 1.0101 0.9974 1.0035 0.9963 1.0098 0.8874 1.0163 0.902
(-1, -1) 1.0103 0.9983 1.0038 0.9961 1.0102 0.8879 1.0304 0.9064
(0, 0) 1.0106 0.9961 1.0003 0.9995 1.0108 0.8859 1.045 0.9101
(1, 1) 1.0086 0.996 0.998 0.9994 1.0086 0.8857 1.0622 0.909
(2, 2) 1.0082 0.9983 0.9975 1.0027 1.0083 0.8881 1.0789 0.9077
(-2, 0) 1.01 0.9973 1.0009 0.9987 1.01 0.8872 1.0157 0.8993
(-1, 1) 1.0109 0.9977 0.999 0.9986 1.0109 0.8868 1.0267 0.9044
(0, 2) 1.011 0.9963 0.9963 0.9987 1.0105 0.8859 1.0413 0.9079
(1, -2) 1.0087 0.9971 1.0028 0.9993 1.0084 0.886 1.0704 0.904
(2, -1) 1.0084 0.9997 1.0036 0.9975 1.0079 0.8886 1.0891 0.8982
(-2, -2) 1.008 0.9992 1.0034 0.9965 1.0087 0.8887 1.0165 0.902
(-1, -1) 1.0112 0.9988 1.0048 0.998 1.0107 0.8877 1.031 0.9068
(0, 0) 1.0111 0.997 1.0013 0.9967 1.0111 0.8872 1.0454 0.9074
(1, 1) 1.0093 0.9963 0.9975 0.9985 1.009 0.8865 1.0621 0.9083
(2, 2) 1.0101 0.9993 0.9977 1.0007 1.0104 0.8884 1.0795 0.9054
(-2, 0) 1.0108 0.9994 1.0011 0.9985 1.0108 0.8884 1.0159 0.8991
(-1, 1) 1.011 0.9982 0.9979 0.9988 1.0113 0.8875 1.0257 0.9039
(0, 2) 1.0119 0.9972 0.9956 0.9972 1.0118 0.8865 1.041 0.9073
(1, -2) 1.0091 0.9973 1.0043 0.9976 1.009 0.8866 1.072 0.903
(2, -1) 1.01 1.0002 1.0014 0.998 1.0091 0.8894 1.0871 0.8974
(-2, -2) 1.0083 1.0001 1.0038 0.9975 1.0082 0.8895 1.0163 0.9018
(-1, -1) 1.0107 0.999 1.0039 0.9971 1.0106 0.8882 1.0305 0.9064
(0, 0) 1.0116 0.9968 1.0005 0.9982 1.0118 0.8866 1.0453 0.9097
(1, 1) 1.0096 0.9955 0.9981 0.9995 1.0095 0.8862 1.0619 0.909
(2, 2) 1.0101 0.9994 0.9968 1.0011 1.0098 0.8889 1.0802 0.9066
(-2, 0) 1.0107 0.9989 1.0008 0.9991 1.0113 0.8886 1.0156 0.8998
(-1, 1) 1.0113 0.9983 0.9989 0.9995 1.011 0.8874 1.0262 0.9055
(0, 2) 1.0116 0.9969 0.9967 0.9976 1.0115 0.8869 1.042 0.9081
(1, -2) 1.0093 0.9975 1.0043 0.999 1.0093 0.8869 1.0721 0.9041
(2, -1) 1.0098 0.9996 1.0024 0.9975 1.0097 0.8891 1.0887 0.8974
(-2, -2) 1.0096 0.9977 1.0034 0.9979 1.0095 0.8875 1.0162 0.9027
(-1, -1) 1.0094 0.9978 1.0038 0.9976 1.0097 0.8872 1.0304 0.9067
(0, 0) 1.0106 0.9963 1.0013 0.9974 1.0104 0.8859 1.0459 0.9085
(1, 1) 1.0085 0.9965 0.9982 1.0001 1.0084 0.8857 1.0621 0.9093
(2, 2) 1.0079 0.9983 0.9961 0.9983 1.0078 0.8879 1.0786 0.9043
(-2, 0) 1.0099 0.9983 1.0007 0.9977 1.01 0.8872 1.0155 0.8988
(-1, 1) 1.0112 0.9976 0.9983 0.9981 1.011 0.8866 1.0262 0.9043
(0, 2) 1.0108 0.9962 0.9959 0.9957 1.0108 0.8863 1.0411 0.906
(1, -2) 1.0078 0.9973 1.0034 0.998 1.0074 0.8864 1.071 0.9031
(2, -1) 1.0082 0.9996 1.0036 0.9969 1.0079 0.8887 1.0881 0.8972
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Table 4: Median parameter estimates investigating the impact of treatment thresholds in a multistage DTR, by varying
(ψ11, ψ21) as indicated. Blip parameter estimates are compared for n = 10000 individuals, using the corrected method
compared to a naive analysis. The top set of rows of the table use the first error-prone proxy at both stages, the second
set of rows use the mean of proxies at both stages, the third set of rows use the mean at the first stage and the first
error-prone proxy at the second, and the final set of rows use the first error-prone proxy at the first stage and the mean
at the second. Bold values indicate parameters for which the 95% percentile-based interval across the 1000 simulation
replicates did not cover the true parameter value.
Regression Calibration Naive
(ψ10, ψ11, ψ20, ψ21) A1 A1X1 A2 A2X2 A1 A1X1 A2 A2X2
(1, -1, 1, -1) 0.9902 -1.001 1.0011 -1.002 0.9907 -0.8904 0.956 -0.9114
(1, -0.1, 1, -0.1) 0.9999 -0.1017 1.0017 -0.1006 0.9998 -0.0904 0.9971 -0.0914
(1, 0, 1, 0) 1 -0.0019 1.0014 -8e-04 1 -0.0017 1.0016 -9e-04
(1, 0.1, 1, 0.1) 0.9998 0.0979 1.0016 0.099 0.9998 0.0872 1.006 0.0904
(1, 1, 1, 1) 1.0106 0.9961 1.0003 0.9995 1.0108 0.8859 1.045 0.9101
(1, -1, 1, 0) 1.0006 -1.0014 1.0017 -1e-04 1.0005 -0.89 1.0017 2e-04
(1, -0.1, 1, 0.1) 0.9998 -0.1018 1.0017 0.0994 0.9998 -0.0905 1.0059 0.0906
(1, 0, 1, 1) 1.0106 -0.0029 1.0017 0.9986 1.0105 -0.0026 1.0461 0.9094
(1, 0.1, 1, -1) 0.9918 0.0988 1.0019 -1.0028 0.9918 0.0877 0.9563 -0.9121
(1, 1, 1, -0.1) 0.9998 0.9967 1.0002 -0.1017 1.0004 0.8867 0.9958 -0.0922
(1, -1, 1, -1) 0.993 -1.0006 0.9997 -1.0023 0.9934 -0.8895 0.9548 -0.911
(1, -0.1, 1, -0.1) 1.0001 -0.1017 0.9993 -0.1018 1.0001 -0.0903 0.9951 -0.0924
(1, 0, 1, 0) 1.0006 -0.0017 0.9995 -0.0017 1.0006 -0.0015 0.9996 -0.0018
(1, 0.1, 1, 0.1) 1.0007 0.0985 0.9999 0.0976 1.0007 0.0875 1.0046 0.0889
(1, 1, 1, 1) 1.0111 0.997 1.0013 0.9967 1.0111 0.8872 1.0454 0.9074
(1, -1, 1, 0) 1.0025 -1.0015 0.9996 -0.0015 1.0025 -0.8903 0.9994 -0.0012
(1, -0.1, 1, 0.1) 1.0006 -0.1016 0.9993 0.0981 1.0006 -0.0903 1.004 0.0895
(1, 0, 1, 1) 1.0117 -0.0015 1.0016 0.9968 1.0117 -0.0013 1.0459 0.9076
(1, 0.1, 1, -1) 0.9924 0.0992 1.0005 -1.0034 0.9925 0.0881 0.9549 -0.9123
(1, 1, 1, -0.1) 0.9997 0.9969 1.0006 -0.1023 1.0001 0.8871 0.9957 -0.0933
(1, -1, 1, -1) 0.9926 -1.0004 1.0011 -1.0041 0.9927 -0.8893 0.9556 -0.913
(1, -0.1, 1, -0.1) 1.0015 -0.1013 1 -0.1008 1.0015 -0.09 0.9959 -0.092
(1, 0, 1, 0) 1.0015 -0.0017 1.0001 -7e-04 1.0015 -0.0015 1 -8e-04
(1, 0.1, 1, 0.1) 1.0018 0.0984 1.0002 0.0991 1.0017 0.0875 1.0046 0.0902
(1, 1, 1, 1) 1.0116 0.9968 1.0005 0.9982 1.0118 0.8866 1.0453 0.9097
(1, -1, 1, 0) 1.0023 -1.0016 1.0008 -0.0011 1.0022 -0.8901 1.0008 -0.0015
(1, -0.1, 1, 0.1) 1.0016 -0.1016 1.0006 0.0994 1.0016 -0.0903 1.0048 0.09
(1, 0, 1, 1) 1.0121 -0.0014 1.0004 0.9982 1.0121 -0.0012 1.045 0.9097
(1, 0.1, 1, -1) 0.9926 0.0996 0.9999 -1.0028 0.9927 0.0885 0.9549 -0.9121
(1, 1, 1, -0.1) 1.001 0.9971 0.9998 -0.1007 1.0009 0.8872 0.9952 -0.0919
(1, -1, 1, -1) 0.9893 -1.0008 1.0004 -1.0018 0.9893 -0.8897 0.9554 -0.9112
(1, -0.1, 1, -0.1) 0.9992 -0.1017 1.0013 -0.1014 0.9992 -0.0906 0.9964 -0.0928
(1, 0, 1, 0) 0.9994 -0.0019 1.0013 -0.0016 0.9993 -0.0017 1.001 -0.0018
(1, 0.1, 1, 0.1) 0.9997 0.0979 1.0012 0.0982 0.9996 0.0873 1.0058 0.0893
(1, 1, 1, 1) 1.0106 0.9963 1.0013 0.9974 1.0104 0.8859 1.0459 0.9085
(1, -1, 1, 0) 1.0008 -1.0013 0.9997 -6e-04 1.0009 -0.8901 0.9996 -8e-04
(1, -0.1, 1, 0.1) 0.9997 -0.1014 1.001 0.0987 0.9996 -0.0903 1.0056 0.0894
(1, 0, 1, 1) 1.0102 -0.0023 1.0011 0.9986 1.0102 -0.002 1.0456 0.9091
(1, 0.1, 1, -1) 0.9914 0.0986 1.0013 -1.0021 0.9914 0.0876 0.9563 -0.9119
(1, 1, 1, -0.1) 0.9994 0.9966 1.0005 -0.1016 0.9995 0.8867 0.9958 -0.0925
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Table 5: Median parameter estimates investigating the impact of treatment probabilities in a multistage DTR, by vary-
ing the true treatment-free model as indicated. Linear treatment-free models are used in all settings. Blip parameter
estimates are compared for n = 10000 individuals, using the corrected method compared to a naive analysis. The top
set of rows of the table use the first error-prone proxy at both stages, the second set of rows use the mean of proxies
at both stages, the third set of rows use the mean at the first stage and the first error-prone proxy at the second, and
the final set of rows use the first error-prone proxy at the first stage and the mean at the second. Bold values indicate
parameters for which the 95% percentile-based interval across the 1000 simulation replicates did not cover the true
parameter value.
Regression Calibration Naive
Treatment-Free Model A1 A1X1 A2 A2X2 A1 A1X1 A2 A2X2
Linear 1.0106 0.9961 1.0003 0.9995 1.0108 0.8859 1.045 0.9101
Quadratic 1.0105 1.0043 1.0012 0.9982 1.0104 0.893 1.0457 0.9098
Cubic 1.0019 1.0108 1.0041 0.9993 1.0021 0.8986 1.0484 0.9099
Exponential 1.0042 1.0105 1.0035 0.9986 1.0041 0.8976 1.0476 0.9104
Complex 1.0125 1.0038 0.9994 1.0007 1.0127 0.8921 1.044 0.9116
Linear 1.0111 0.997 1.0013 0.9967 1.0111 0.8872 1.0454 0.9074
Quadratic 1.0106 1.0017 1.0033 0.9959 1.0107 0.8901 1.0483 0.9078
Cubic 1.0069 1.0043 1.0072 1.0012 1.0068 0.8938 1.0525 0.9129
Exponential 1.0089 1.0066 1.0054 1.0015 1.0091 0.8939 1.0503 0.9122
Complex 1.0113 1.0014 1.0035 0.9969 1.0116 0.8903 1.0467 0.9082
Linear 1.0116 0.9968 1.0005 0.9982 1.0118 0.8866 1.0453 0.9097
Quadratic 1.0116 1.001 1.0005 0.9985 1.0115 0.8897 1.044 0.9093
Cubic 1.0075 1.0034 1.0038 0.9967 1.0075 0.8937 1.0484 0.9095
Exponential 1.0091 1.0069 1.0033 0.9996 1.0087 0.8949 1.0477 0.9107
Complex 1.0119 1.0026 1 1.0012 1.0116 0.8904 1.0445 0.9108
Linear 1.0106 0.9963 1.0013 0.9974 1.0104 0.8859 1.0459 0.9085
Quadratic 1.01 1.004 1.003 0.997 1.0104 0.8927 1.0472 0.9078
Cubic 1.0017 1.0101 1.0044 0.9992 1.0021 0.8974 1.0504 0.9104
Exponential 1.0046 1.0097 1.0061 0.9996 1.0045 0.8975 1.0503 0.9104
Complex 1.0115 1.0039 1.0015 0.9985 1.0115 0.8926 1.0457 0.9091
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Table 6: Median parameter estimates investigating the impact of treatment probabilities in a multistage DTR, by
varying the treatment models as indicated. Linear treatment models are used in all situations. Blip parameter estimates
are compared for n = 10000 individuals, using the corrected method compared to a naive analysis. The top set of rows
of the table use the first error-prone proxy at both stages, the second set of rows use the mean of proxies at both stages,
the third set of rows use the mean at the first stage and the first error-prone proxy at the second, and the final set of
rows use the first error-prone proxy at the first stage and the mean at the second. Bold values indicate parameters for
which the 95% percentile-based interval across the 1000 simulation replicates did not cover the true parameter value.
Regression Calibration Naive
Treatment Models A1 A1X1 A2 A2X2 A1 A1X1 A2 A2X2
Linear/Linear 1.0106 0.9961 1.0003 0.9995 1.0108 0.8859 1.045 0.9101
Linear/Quadratic 0.9992 0.9992 0.8902 1.1138 0.9991 0.8881 0.9407 1.014
Linear/Mixed 0.9925 1 0.9022 1.1187 0.9923 0.8893 0.9529 1.0174
Linear/Exponential 1.0126 0.9989 0.9836 1.016 1.0124 0.8876 1.0291 0.9257
Quadratic/Quadratic 0.9047 1.1117 0.8929 1.1153 0.9044 0.9885 0.9611 1.0159
Quadratic/Mixed 0.8969 1.1119 0.9011 1.1188 0.897 0.9886 0.9707 1.0199
Quadratic/Exponential 0.918 1.1125 0.9846 1.0189 0.918 0.9899 1.0478 0.9289
Mixed/Mixed 0.9033 1.1052 0.9078 1.1216 0.9033 0.9824 0.9946 1.0192
Mixed/Exponential 0.9246 1.1096 0.9853 1.0153 0.9244 0.9872 1.0652 0.9223
Exponential/Exponential 0.9979 1.013 0.9853 1.0131 0.9983 0.9007 1.0479 0.9244
Linear/Linear 1.0111 0.997 1.0013 0.9967 1.0111 0.8872 1.0454 0.9074
Linear/Quadratic 1.0013 0.9987 0.8847 1.1219 1.0012 0.8876 0.9353 1.0215
Linear/Mixed 0.9915 0.9979 0.8915 1.1179 0.9916 0.8868 0.9413 1.0179
Linear/Exponential 1.0128 0.999 0.9818 1.0194 1.013 0.8882 1.0271 0.9275
Quadratic/Quadratic 0.898 1.1245 0.8863 1.1239 0.8982 0.9994 0.9547 1.0234
Quadratic/Mixed 0.8889 1.1226 0.8943 1.1241 0.8887 0.9981 0.9629 1.0257
Quadratic/Exponential 0.9089 1.121 0.9809 1.021 0.9087 0.9965 1.0429 0.932
Mixed/Mixed 0.8941 1.1119 0.9053 1.1241 0.8938 0.9878 0.9923 1.0228
Mixed/Exponential 0.9142 1.1125 0.9834 1.0242 0.9141 0.9884 1.0622 0.9313
Exponential/Exponential 0.9945 1.0162 0.9831 1.0186 0.9948 0.9021 1.0474 0.9294
Linear/Linear 1.0116 0.9968 1.0005 0.9982 1.0118 0.8866 1.0453 0.9097
Linear/Quadratic 1.0012 0.9979 0.8904 1.1137 1.0008 0.8876 0.9412 1.0139
Linear/Mixed 0.9922 0.9985 0.8999 1.1146 0.9923 0.8881 0.9495 1.0143
Linear/Exponential 1.011 0.9982 0.9823 1.0161 1.0112 0.8869 1.0281 0.9263
Quadratic/Quadratic 0.8978 1.1239 0.8921 1.1151 0.8982 0.9981 0.9598 1.0149
Quadratic/Mixed 0.8904 1.1216 0.9021 1.1175 0.8903 0.9979 0.9703 1.0182
Quadratic/Exponential 0.9086 1.1215 0.9848 1.0112 0.9083 0.9972 1.0464 0.923
Mixed/Mixed 0.8932 1.1145 0.9077 1.1196 0.8937 0.9898 0.9943 1.0184
Mixed/Exponential 0.9133 1.1123 0.9854 1.0169 0.9126 0.9888 1.0637 0.9247
Exponential/Exponential 0.996 1.0178 0.9844 1.0135 0.9955 0.905 1.0486 0.9253
Linear/Linear 1.0106 0.9963 1.0013 0.9974 1.0104 0.8859 1.0459 0.9085
Linear/Quadratic 1.0003 0.9973 0.884 1.1229 0.9997 0.8868 0.9348 1.0231
Linear/Mixed 0.9908 0.998 0.8919 1.1214 0.9904 0.8869 0.9419 1.0213
Linear/Exponential 1.0111 0.9987 0.9803 1.0186 1.0113 0.888 1.0264 0.9292
Quadratic/Quadratic 0.9049 1.1118 0.8872 1.1245 0.9041 0.9884 0.9563 1.0241
Quadratic/Mixed 0.8951 1.1141 0.8978 1.1272 0.8956 0.9901 0.9677 1.0279
Quadratic/Exponential 0.9178 1.1119 0.9811 1.0225 0.9179 0.9884 1.0437 0.9333
Mixed/Mixed 0.9008 1.1039 0.9066 1.1307 0.901 0.9811 0.9946 1.0289
Mixed/Exponential 0.9248 1.1063 0.9843 1.023 0.9249 0.9835 1.0644 0.9311
Exponential/Exponential 0.9971 1.0136 0.984 1.0232 0.997 0.9008 1.0482 0.9345
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Table 7: Median parameter estimates investigating the impact of treatment probabilities in a multistage DTR, by
varying the error-models as indicated. Blip parameter estimates are compared for n = 10000 individuals, using the
corrected method compared to a naive analysis. The top set of rows of the table use the first error-prone proxy at both
stages, the second set of rows use the mean of proxies at both stages, the third set of rows use the mean at the first
stage and the first error-prone proxy at the second, and the final set of rows use the first error-prone proxy at the first
stage and the mean at the second. Bold values indicate parameters for which the 95% percentile-based interval across
the 1000 simulation replicates did not cover the true parameter value.
Regression Calibration Naive
Error Models A1 A1X1 A2 A2X2 A1 A1X1 A2 A2X2
Normal/Normal 1.0106 0.9961 1.0003 0.9995 1.0108 0.8859 1.045 0.9101
Normal/Approx. Normal 1.0175 0.9954 1.0007 0.9975 1.0174 0.8248 1.0705 0.8586
Normal/Gamma 1.0109 1.0292 1.0036 1.0078 1.0103 0.8577 1.0749 0.8647
Normal/Uniform 1.0062 1.034 1.0028 1.0226 1.0062 0.9729 1.0339 0.9616
Approx. Normal/Approx. Normal 1.0428 0.996 0.9989 0.9916 1.0414 0.6132 1.1612 0.6666
Approx. Normal/Gamma 1.0187 1.1453 1.0069 1.0592 1.019 0.7388 1.1893 0.7095
Approx. Normal/Uniform 1.0109 1.0405 1.0028 1.0318 1.0107 0.9659 1.0443 0.9495
Gamma/Gamma 1.0866 1.2838 0.919 1.202 1.086 0.857 1.1308 0.8097
Gamma/Uniform 1.0157 1.0608 0.9766 1.0494 1.0156 0.9842 1.0198 0.9638
Uniform/Uniform 1.0075 1.0367 0.991 1.043 1.0076 0.9957 1.0152 0.9957
Normal/Normal 1.0111 0.997 1.0013 0.9967 1.0111 0.8872 1.0454 0.9074
Normal/Approx. Normal 1.0173 0.9968 1.0002 0.9994 1.0165 0.8249 1.0706 0.8586
Normal/Gamma 1.0247 1.0323 0.9832 1.0201 1.0248 0.8602 1.0552 0.877
Normal/Uniform 1.0103 1.0358 0.995 1.0339 1.0098 0.9747 1.0269 0.9718
Approx. Normal/Approx. Normal 1.0393 1.008 0.9994 0.9984 1.0384 0.6209 1.163 0.6743
Approx. Normal/Gamma 1.0537 1.1959 0.9615 1.1174 1.0534 0.7688 1.1499 0.7544
Approx. Normal/Uniform 1.0104 1.0498 0.9957 1.0521 1.0101 0.9743 1.0383 0.9692
Gamma/Gamma 1.0951 1.4009 0.9042 1.3366 1.0947 0.9351 1.1268 0.952
Gamma/Uniform 1.0161 1.0605 0.9816 1.0662 1.0159 0.9859 1.025 0.9803
Uniform/Uniform 1.0079 1.033 0.9914 1.0418 1.0077 0.9923 1.0154 0.9942
Normal/Normal 1.0116 0.9968 1.0005 0.9982 1.0118 0.8866 1.0453 0.9097
Normal/Approx. Normal 1.0177 0.9966 1.0008 0.9977 1.0171 0.8257 1.0708 0.8578
Normal/Gamma 1.0263 1.0326 1.0028 1.0074 1.0262 0.86 1.0744 0.8649
Normal/Uniform 1.0112 1.036 1.0029 1.0235 1.0112 0.9746 1.0344 0.9619
Approx. Normal/Approx. Normal 1.0372 1.0098 0.9988 0.9909 1.037 0.6207 1.162 0.6673
Approx. Normal/Gamma 1.0495 1.1943 1.007 1.058 1.0493 0.7689 1.1893 0.7076
Approx. Normal/Uniform 1.0116 1.0498 1.0027 1.0313 1.0117 0.9742 1.0453 0.9487
Gamma/Gamma 1.072 1.4024 0.9193 1.2012 1.0719 0.9346 1.1294 0.809
Gamma/Uniform 1.0161 1.0601 0.9755 1.0494 1.016 0.9857 1.0197 0.9645
Uniform/Uniform 1.0078 1.0329 0.9916 1.0433 1.0078 0.9924 1.0156 0.9957
Normal/Normal 1.0106 0.9963 1.0013 0.9974 1.0104 0.8859 1.0459 0.9085
Normal/Approx. Normal 1.017 0.9955 1.0009 0.9985 1.0166 0.8249 1.0704 0.8581
Normal/Gamma 1.0095 1.0288 0.9834 1.0218 1.0089 0.8568 1.0569 0.8763
Normal/Uniform 1.0047 1.034 0.9952 1.0332 1.0048 0.9736 1.0266 0.9711
Approx. Normal/Approx. Normal 1.0441 0.997 0.9987 0.9996 1.0439 0.6129 1.1602 0.6746
Approx. Normal/Gamma 1.0232 1.1462 0.9612 1.1165 1.023 0.7378 1.1498 0.7538
Approx. Normal/Uniform 1.0101 1.0408 0.9958 1.0529 1.0102 0.9655 1.0377 0.969
Gamma/Gamma 1.1095 1.2825 0.904 1.337 1.1087 0.8556 1.1267 0.9509
Gamma/Uniform 1.016 1.0603 0.9816 1.0659 1.0159 0.9845 1.0256 0.9818
Uniform/Uniform 1.0074 1.0369 0.9916 1.0424 1.0074 0.9957 1.0157 0.9946
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